GlassScriptPhysician profile
Andy D Tran
NPI 1326059882
$66,713.78
in general payments reported to CMS, 2019-2025
16 companies · $11K in 2025
The $11K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $3,950 · 2021: $4,558 · 2022: $8,223 · 2023: $11K · 2024: $18K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $4,672 · Consulting Fee: $2,100 · Travel and Lodging: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,040.00 |
| Food and Beverage | $4,672.35 |
| Consulting Fee | $2,100.00 |
| Travel and Lodging | $1,044.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $65,847.97 | 2019-2025 | Opsumit, Uptravi |
| Pfizer INC. | $290.20 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $121.62 | 2019-2024 | Xarelto |
| Biosense Webster, INC. | $109.56 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $103.08 | 2020-2025 | Eliquis, Opdualag |
| Abiomed | $60.27 | 2025 | |
| Kestra Medical Technology Services, INC. | $49.37 | 2024 | Assure Wcd |
| Medtronic, INC. | $28.47 | 2021 | |
| Alkermes, INC. | $23.39 | 2025 | Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $20.15 | 2019 | |
| Aurobindo Pharma USA, INC. | $16.85 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $13.37 | 2024 | Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.25 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.